Learning Objectives - Diabetes Mellitus Flashcards

1
Q

Diagnostic criteria for impaired fasting glucose?

A

Fasting glucose between 110-125 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Diagnostic criteria for impaired glucose tolerance?

A

2 hour postprandial glucose between 140-199 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pre-diabetes criteria?

A

HbA1c 5.7-6.4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is diabetes diagnosed?

A
  1. 2 fasting glucose measurements of 126+ (preferred screening etst)
  2. Random plasma glucose level 200+ with symptoms
  3. Two hour postprandial plasma glucose level >200
  4. A1C 6.5+

Need 2 separate tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why is obesity the greatest risk factor for DM2?

A

Increased plasma levels of free fatty acids make muscles more insulin resistant, reduces glucose uptake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

True or false - the genetic component is stronger in DM1 than DM2.

A

False - stronger in DM2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Presenting signs and symptoms of DKA?

A

Hyperglycemia >450
AG metabolic acidosis (serum pH <7.2
Ketosis
Kussmaul respirations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Presenting signs and symptoms of HHS?

A

Hyperglycemia >900
Hyperosmolarity >320
Serum pH >7.3 (no acidosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cause of hyponatremia in DKA?

A

Osmotic shift of fluid from ICF to ECF (total body sodium is normal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cause of hyperkalemia/hypokalemia in DKA?

A

Acidosis initially causes hyperkalemia, although total body potassium is low. As insulin is given, K shifts into cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why is ketogenesis minimal in HHS?

A

Small amount of insulin is related to blunt glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Labs needed to screen/diagnose/follow patients with DM?

A
Glucose
Electrolytes
BUN/Cr
Fasting lipids
HgA1C
Urine microalubmin/creatinine ratio
Urine dipstick
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pros of sulfonylureas?

A

Efficacious (decrease A1C 1.2%)
Increase insulin secretion
Long track record
Inexpensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cons of sulfonylureas?

A

Hypoglycemia
Weight gain
Failure in 3-5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pros of metformin?

A

Efficacious (decrease A1C 1.2%)
Long track record
Decreases hepatic glucose production (90%)
Helps increase muscle glucose uptake (10%)
Protective against colon cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cons of metformin?

A

GI upset
Hold for procedures and CT dye load
D/C if Creatinine >1.5 mg

17
Q

Pros of thiazoladinediones?

A

Efficacious
Reasonably long experience
No hypoglycemia
Beta cell preservation

18
Q

Cons of thiazoladinediones?

A
Increased CV risk?
Bladder cancer?
Edema
Weight Gain
Fractures
19
Q

Pros of GLP-1 mimetics?

A
Efficacious (decrease A1C 1.2-1.5%)
Decrease post-prandial glucose
-No hypoglycemia
-Potential for weight loss
-Possible beta cell preservation
20
Q

Cons of GLP-1 mimetics?

A

Daily/2x daily/weekly injection
GI upset
Rare reports of pancreatitis
Cost

21
Q

Pros of DPP-4 inhibitors?

A
Efficacious (decrease A1C 0.7%)
Decrease post-prandial glucose
No hypoglycemia
Weight neutral
Safe in renal disease
No Gi upset
Possible beta cell preservation
22
Q

Cons of DDP-4 inhibitors?

A

Cost

Rare reports of pancreatitis

23
Q

Pros of alpha-glucosidase inhibitors?

A

Efficacious (decrease A1C 0.5%)
Long experience
No hypoglycemia
No weight gain

24
Q

Cons of alpha-glucosidase inhibiators?

A

Dosing with meals

GI intolerance

25
Q

Pros of quick release bromocriptine?

A

Efficacoius (decreases A1C 0.5%)
Resets hypothalamic circadian clock
Surprisingly good CV profile

26
Q

Cons of quick release bromocriptine?

A

Hypotension
Short track record
Cost

27
Q

Pros of SGLT-2 inhibitors?

A

Efficacious (decrease A1C 1.0%)
Inhibits glucose reabsorption at renal level
Weight reduction
No drug interactions

28
Q

Cons of SGLT-2 inhibitors?

A

Increased UTIs/vaginitis
Short track record
Cost

29
Q

Dietary recommendations for DM1 and DM2?

A

DASH

30
Q

Manage DKA

A
  1. IV insulin immediately (prime with 0.1 U/kg regular insulin, then infusion 0.1 units/kg/hour)
    - Ensure pt is not hypokalemic
    - Continue insulin until AG closes and metabolic acidosis is corrected
    - When eating again, transition to SubQ
  2. IVF (NS) immediately
    - Add 5% glucose once blood glucose reaches 250 to prevent hypoglycemia
  3. Replace potassium prophylactically with IV fluids
    - Monitor/replete K, Mg, Phos
  4. Bicarb replacement controversial, not necessary in most cases
31
Q

NKH management?

A
  1. Fluid replacement most important - NS, switch to half NS when stable, add 5% glucose once blood glucose reaches 250 mg/dL to prevent hypoglycemia
  2. 5-10 unit bolus insulin, then low dose infusion 2-4 units/hr
32
Q

Basic management of blood glucose in the hospitalized patient?

A

Insulin sliding scale of regular insulin doses based on finger-stick
Monitor blood glucose Q4x daily

33
Q

HTN goals in DM

A

SBP <140
SBP <130 if can be achieved without undue treatment burden
DBP <90

At least one anti-HTN med at bedtime

34
Q

Lipid goals in DM

A

LDL <100 if no overt CVD
If CVD or 40+ with 1+ risk factor, LDL <70
HDL >40
TG <150
TC<200
LDL targeted statin therapy is preferred strategy

35
Q

Mechanism of metformin?

A

Decreased hepatic glucose output via decreasing glycogenolysis and gluconeogenesis

36
Q

How are microvascular complications evaluated?

A

Eye exam
Microalbumin
Foot care

37
Q

How are macrovascular complications evaluated?

A

Carotid Doppler

ABI

38
Q

Which patients with DM should get aspirin for primary prevention?

A

Patients with DM1/2 at increased CV risk